Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Biotechnology

Editor-in-Chief

ISSN (Print): 1389-2010
ISSN (Online): 1873-4316

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Letter Article

Should the Vancomycin Minimal Inhibitory Concentration be used as an Infant Critical Care Regular Criteria?

Author(s): Nadielle S. Bidu, Bruno J.D. Fernandes, Jucelino N.C. Filho, Regina E.A. Bastos, Joice N.R. Pedreira and Ricardo D. Couto*

Volume 21, Issue 11, 2020

Page: [1052 - 1058] Pages: 7

DOI: 10.2174/1389201021666200327162402

Price: $65

Abstract

Background: Vancomycin is the first-line antibiotic used for the treatment of staphylococcal infections. Because of its narrow therapeutic window and the pharmacokinetics variability, vancomycin trough serum concentration should be monitored. However, due to the increased cases of staphylococcus’ commensal species infections and the case of vancomycin resistance, the minimal inhibitory concentration should be considered on antimicrobial therapy.

Objective: This article aimed to show the importance of the minimal inhibitory concentration to infants on vancomycin therapy as regular criteria.

Materials and Methods: Three infants in the use of vancomycin, hospitalized in the same maternity hospital, and that had at least one blood culture performed during the intensive-care-unit hospitalization were included in the study. Vancomycin serum concentrations were determined by particleenhanced- turbidimetric inhibition-immunoassay. The vancomycin minimal inhibitory concentration data were interpreted by following the Clinical and Laboratory Standards Institute (CLSI) and the European Committee on Antimicrobial Susceptibility Testing (EUCAST). The trough serum concentration range of 10 to 20 mg.L-1 was considered therapeutic.

Results: All three patients had at least one infection by S. epidermidis, being one patient exhibit vancomycin- resistant S. epidermidis infection. All patients had stoppages in the vancomycin treatment, and the minimal inhibitory concentration was performed for only one patient.

Conclusion: The data obtained from these patients also showed the need to perform therapeutic monitoring by using minimal inhibitory concentration values, because, although the serum concentrations were within the reference range, they are insufficient to guarantee patient therapeutic success.

Keywords: Infants vancomycin therapy, minimal inhibitory concentration, drug monitoring, antibiotic resistance, blood culture, Staphylococcus epidermidis.

« Previous Next »
Graphical Abstract

[1]
da Silva, A.C.S.S.; dos Santos, É.I.; Penha, R.S.; Dutra, L.B.; Barreiros, R.N.; Ribeiro, I.V. Evidências científicas brasileiras acerca da infecção primária da corrente sanguínea em pediatria. Rev. Enferm. Atual., 2017, 82, 62-70.
[2]
Peleg, A.Y.; Hooper, D.C. Hospital-acquired infections due to gram-negative bacteria. N. Engl. J. Med., 2010, 362(19), 1804-1813.
[http://dx.doi.org/10.1056/NEJMra0904124] [PMID: 20463340]
[3]
Dasgupta, S.; Das, S.; Chawan, N.S.; Hazra, A. Nosocomial infections in the intensive care unit: Incidence, risk factors, outcome and associated pathogens in a public tertiary teaching hospital of Eastern India. Indian J. Crit. Care Med., 2015, 19(1), 14-20.
[http://dx.doi.org/10.4103/0972-5229.148633] [PMID: 25624645]
[4]
Chong, J.; Quach, C.; Blanchard, A.C.; Poliquin, P.G.; Golding, G.R.; Laferrière, C.; Lévesque, S. Molecular epidemiology of a vancomycin-intermediate heteroresistant Staphylococcus epidermidis outbreak in a neonatal intensive care unit. Antimicrob. Agents Chemother., 2016, 60(10), 5673-5681.
[http://dx.doi.org/10.1128/AAC.00726-16] [PMID: 27401579]
[5]
Wang, N.; Neilan, A.M.; Klompas, M. Staphylococcus intermedius infections: Case report and literature review. Infect. Dis. Rep., 2013, 5(1), e3.
[http://dx.doi.org/10.4081/idr.2013.e3] [PMID: 24470954]
[6]
Cavanagh, J.P.; Wolden, R.; Heise, P.; Esaiassen, E.; Klingenberg, C.; Aarag, F.E.G. Antimicrobial susceptibility and body site distribution of community isolates of coagulase-negative staphylococci. APMIS, 2016, 124(11), 973-978.
[http://dx.doi.org/10.1111/apm.12591] [PMID: 27599662]
[7]
Ahmed, A.; Satti, L.; Zaman, G.; Gardezi, A.; Sabir, N.; Khadim, M.T. Catheter related recurrent blood stream infection caused by linezolid-resistant, methicillin resistant Staphylococcus haemolyticus; An emerging super bug. J. Pak. Med. Assoc., 2019, 69(2), 261-263.
[PMID: 30804597]
[8]
Mashaly, G.E.S.; El-Mahdy, R.H. Vancomycin heteroresistance in coagulase negative Staphylococcus blood stream infections from patients of intensive care units in Mansoura University Hospitals, Egypt. Ann. Clin. Microbiol. Antimicrob., 2017, 16(1), 63.
[http://dx.doi.org/10.1186/s12941-017-0238-5] [PMID: 28927452]
[9]
Sinkeler, F.S.; de Haan, T.R.; Hodiamont, C.J.; Bijleveld, Y.A.; Pajkrt, D.; Mathôt, R.A.A. Inadequate vancomycin therapy in term and preterm neonates: A retrospective analysis of trough serum concentrations in relation to minimal inhibitory concentrations. BMC Pediatr., 2014, 14(1), 193.
[http://dx.doi.org/10.1186/1471-2431-14-193] [PMID: 25066951]
[10]
Pereira, V.C. Cunha, Mde. L. Coagulase-negative staphylococci strains resistant to oxacillin isolated from neonatal blood cultures. Mem. Inst. Oswaldo Cruz, 2013, 108(7), 939-942.
[http://dx.doi.org/10.1590/0074-0276130644] [PMID: 24141968]
[11]
Chong, J.; Caya, C.; Lévesque, S.; Quach, C. Heteroresistant vancomycin intermediate coagulase negative staphylococcus in the NICU: A systematic review. PLoS One, 2016, 11(10), e0164136.
[http://dx.doi.org/10.1371/journal.pone.0164136] [PMID: 27716838]
[12]
Yamada, K.; Namikawa, H.; Fujimoto, H.; Nakaie, K.; Takizawa, E.; Okada, Y.; Fujita, A.; Kawaguchi, H.; Nakamura, Y.; Abe, J.; Kaneko, Y.; Kakeya, H. clinical characteristics of methicillin-resistant coagulase-negative staphylococcal bacteremia in a tertiary hospital. Intern. Med., 2017, 56(7), 781-785.
[http://dx.doi.org/10.2169/internalmedicine.56.7715] [PMID: 28381743]
[13]
van Hal, S.J.; Lodise, T.P.; Paterson, D.L. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: A systematic review and meta-analysis. Clin. Infect. Dis., 2012, 54(6), 755-771.
[http://dx.doi.org/10.1093/cid/cir935] [PMID: 22302374]
[14]
Macdougall, C.; Chambers, H.F. Inibidores da síntese de proteínas e agentes antibacterianos diversos. Goodman & Gilman’s as bases farmacológicas da terapêutica, 12th ed; Brunton, L.L., Ed.; McGraw-Hill Interamericana do Brasil: Rio de Janeiro, 2012, pp. 1521-1547.
[15]
Srinivasan, A.; Dick, J.D.; Perl, T.M. Vancomycin resistance in staphylococci. Clin. Microbiol. Rev., 2002, 15(3), 430-438.
[http://dx.doi.org/10.1128/CMR.15.3.430-438.2002] [PMID: 12097250]
[16]
Sujatha, S.; Praharaj, I. Glycopeptide resistance in gram-positive cocci: A review. Interdiscip. Perspect. Infect. Dis., 2012, 2012781679
[http://dx.doi.org/10.1155/2012/781679] [PMID: 22778729]
[17]
Moellering, R.C. Jr, Vancomycin: A 50-year reassessment. Clin. Infect. Dis. 2006, 42(Supplement_1), S3-4.
[18]
Rybak, M.J.; Lomaestro, B.M.; Rotschafer, J.C.; Moellering, R.C.; Craig, W.A.; Billeter, M.; Dalovisio, J.R.; Levine, D.P. Vancomycin therapeutic guidelines: A summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin. Infect. Dis., 2009, 49(3), 325-327.
[http://dx.doi.org/10.1086/600877] [PMID: 19569969]
[19]
Abdul-Aziz, M.H.; Lipman, J.; Mouton, J.W.; Hope, W.W.; Roberts, J.A. Applying pharmacokinetic/pharmacodynamic principles in critically ill patients: Optimizing efficacy and reducing resistance development. Semin. Respir. Crit. Care Med., 2015, 36(1), 136-153.
[http://dx.doi.org/10.1055/s-0034-1398490] [PMID: 25643277]
[20]
Silva, D.C.B.; Seixas, G.T.F.; Araújo, O.R.; Arduini, R.G.; Carlesse, F.A.; Petrilli, A.S. Vancomycin serum concentrations in pediatric oncologic/hematologic intensive care patients. Braz. J. Infect. Dis., 2012, 16(4), 361-365.
[http://dx.doi.org/10.1016/j.bjid.2012.06.011] [PMID: 22846125]
[21]
Santos, A.B.; Duarte, A.; Saião, A.S. Vancomycin in clinical practice - a review. JBBR, 2011, 8(2), 321-327.
[22]
Eyler, R.F.; Mueller, B.A. Antibiotic pharmacokinetic and pharmacodynamic considerations in patients with kidney disease. Adv. Chronic Kidney Dis., 2010, 17(5), 392-403.
[http://dx.doi.org/10.1053/j.ackd.2010.05.007] [PMID: 20727509]
[23]
James, C.W.; Gurk-Turner, C. Recommendations for monitoring serum vancomycin concentrations. Proc. Bayl. Univ. Med. Cent., 2001, 14(2), 189-190.
[http://dx.doi.org/10.1080/08998280.2001.11927763] [PMID: 16369617]
[24]
Andrews, J.M. Determination of minimum inhibitory concentrations. J. Antimicrob. Chemother., 2001, 48(Suppl. 1), 5-16.
[http://dx.doi.org/10.1093/jac/48.suppl_1.5] [PMID: 11420333]
[25]
Benner, K.W.; Worthington, M.A.; Kimberlin, D.W.; Hill, K.; Buckley, K.; Tofil, N.M. Correlation of vancomycin dosing to serum concentrations in pediatric patients: A retrospective database review. J. Pediatr. Pharmacol. Ther., 2009, 14(2), 86-93.
[PMID: 23055895]
[26]
Navarini, A.; Martino, M.D.V.; Sasagawa, S.M.; Massaia, I.F.D.; Mimica, M.J. Accuracy of a vancomycin brain heart infusion screening plate for the screening of Staphylococcus aureus isolates with increased vancomycin minimum inhibitory concentrations. New Microbiol., 2015, 38(3), 423-426.
[PMID: 26147148]
[27]
Yamamoto, M.; Kuzuya, T.; Baba, H.; Yamada, K.; Nabeshima, T. Population pharmacokinetic analysis of vancomycin in patients with gram-positive infections and the influence of infectious disease type. J. Clin. Pharm. Ther., 2009, 34(4), 473-483.
[http://dx.doi.org/10.1111/j.1365-2710.2008.01016.x] [PMID: 19583681]
[28]
Ambrose, P.J.; Winter, M. Farmacocinética Clínica Básica, Winter, 4ª Ed.; São Paulo, , 2012; pp. 393-409.
[29]
Pacifici, G.M.; Allegaert, K. Clinical pharmacokinetics of vancomycin in the neonate. A review. Clinics (São Paulo) 2012, 67(7), 831-837.
[http://dx.doi.org/10.6061/clinics/2012(07)21] [PMID: 22892931]
[30]
Marqués-Miñana, M.R.; Saadeddin, A.; Peris, J.E. Population pharmacokinetic analysis of vancomycin in neonates. A new proposal of initial dosage guideline. Br. J. Clin. Pharmacol., 2010, 70(5), 713-720.
[http://dx.doi.org/10.1111/j.1365-2125.2010.03736.x] [PMID: 21039765]
[31]
Ye, Z.K.; Li, C.; Zhai, S.D. Guidelines for therapeutic drug monitoring of vancomycin: A systematic review. PLoS One, 2014, 9(6), e99044.
[http://dx.doi.org/10.1371/journal.pone.0099044] [PMID: 24932495]
[32]
Avent, M.L.; Vaska, V.L.; Rogers, B.A.; Cheng, A.C.; van Hal, S.J.; Holmes, N.E.; Howden, B.P.; Paterson, D.L. Vancomycin therapeutics and monitoring: A contemporary approach. Intern. Med. J., 2013, 43(2), 110-119.
[http://dx.doi.org/10.1111/imj.12036] [PMID: 23185970]
[33]
Frye, R.F., Jr; Capitano, B.; Matzke, G.R. Vancomycin. In: Clinical Pharmacokinetics, 3ªed; Murphy, John.E., Ed.; American Society of Health-System Pharmacists: Bethesda, Maryland, 2005, pp. 349-364.
[34]
Ye, Z.K.; Tang, H.L.; Zhai, S.D. Benefits of therapeutic drug monitoring of vancomycin: A systematic review and meta-analysis. PLoS One, 2013, 8(10), e77169.
[http://dx.doi.org/10.1371/journal.pone.0077169] [PMID: 24204764]
[35]
Performance Standards for Antimicrobial Susceptibility Testing. In: CLSI supplement M100. 28th ed.; Clinical and Laboratory Standards Institute Wayne, Pennsylvania, USA, 2018.
[36]
Data from the EUCAST MIC distribution website, http://www.eucast.org
[37]
Florio, W.; Morici, P.; Ghelardi, E.; Barnini, S.; Lupetti, A. Recent advances in the microbiological diagnosis of bloodstream infections. Crit. Rev. Microbiol., 2018, 44(3), 351-370.
[http://dx.doi.org/10.1080/1040841X.2017.1407745] [PMID: 29185372]
[38]
Bidu, N.S.; Fernandes, B.J.D.; Dias, E.J.C.; Filho, J.N.C.; Bastos, R.E.A.; Godoy, A.L.P.C.; Azeredo, F.J.; Pedreira, J.N.R.; Couto, R.D. Vancomycin therapeutic regime adjustment in newborns and infants with bacterial infection: Case series. Curr. Pharm. Biotechnol., 2019, 20(4), 346-351.
[http://dx.doi.org/10.2174/1389201020666190319161511] [PMID: 30892160]
[39]
Santos, R.G.; Alves, C.D.S.; Lemos, L.B.; de Jesus, I.S.; Lemos, G da S. Prescrições de antimicrobianos de uso restrito de pacientes internados em um hospital e ensino. Rev Bras Farm Hosp e Serviços Saúde, 2016, 7(1), 8-12.
[40]
Mehl, A.; Åsvold, B.O.; Kümmel, A.; Lydersen, S.; Paulsen, J.; Haugan, I. Trends in antimicrobial resistance and empiric antibiotic therapy of bloodstream infections at a general hospital in Mid-Norway: A prospective observational study. BMC Infect. Dis., 2017, 17(1), 1-11.
[PMID: 28049444]
[41]
Kelly, S.; Collins, J.; Maguire, M.; Gowing, C.; Flanagan, M.; Donnelly, M.; Murphy, P.G. An outbreak of colonization with linezolid-resistant Staphylococcus epidermidis in an intensive therapy unit. J. Antimicrob. Chemother., 2008, 61(4), 901-907.
[http://dx.doi.org/10.1093/jac/dkn043] [PMID: 18272512]
[42]
Pinheiro, L.; Brito, C.I.; Pereira, V.C.; Oliveira, A.; Camargo, C.H.; Cunha, M.L. Reduced susceptibility to vancomycin and biofilm formation in methicillin-resistant Staphylococcus epidermidis isolated from blood cultures. Mem. Inst. Oswaldo Cruz, 2014, 109(7), 871-878.
[http://dx.doi.org/10.1590/0074-0276140120] [PMID: 25410990]
[43]
Dong, Y.; Chen, S.; Wang, Z.; Peng, N.; Yu, J. Synergy of ultrasound microbubbles and vancomycin against Staphylococcus epidermidis biofilm. J. Antimicrob. Chemother., 2013, 68(4), 816-826.
[http://dx.doi.org/10.1093/jac/dks490] [PMID: 23248238]
[44]
Kononova, L.I.; Filatova, L.B.; Eroshenko, D.V.; Korobov, V.P. Suppression of development of vancomycin-resistant Staphylococcus epidermidis by low-molecular-weight cationic peptides of the lantibiotic family. Microbiology, 2017, 86(5), 571-582.
[http://dx.doi.org/10.1134/S0026261717050125]
[45]
Martínez-Meléndez, A.; Morfín-Otero, R.; Villarreal-Treviño, L.; Camacho-Ortíz, A.; González-González, G.; Llaca-Díaz, J.; Rodríguez-Noriega, E.; Garza-González, E. Molecular epidemiology of coagulase-negative bloodstream isolates: Detection of Staphylococcus epidermidis ST2, ST7 and linezolid-resistant ST23. Braz. J. Infect. Dis., 2016, 20(5), 419-428.
[http://dx.doi.org/10.1016/j.bjid.2016.05.007] [PMID: 27393769]
[46]
Division of Infectious Disease Epidemiology (DIDE). Healthcare Associated Infections (HAI) Outbreak Investigation /Notification Protocol. August, 2014, last accessed 27 March 2019.www.dide.wv.gov
[47]
Zanotto, M.B.; Wappler, P.R.; d’Azevedo, P.A.; Carneiro, M.; Rauber, J.M.; Valim, A.R.M. Avaliação dos níveis séricos de vancomicina em pacientes internados em um hospital de ensino da região central do Rio Grande do Sul - Brasil. Rev Jovens Pesqui, 2014, 4(3), 38-51.
[http://dx.doi.org/10.17058/rjp.v4i3.4589]
[48]
Song, K.H.; Kim, M.; Kim, C.J.; Cho, J.E.; Choi, Y.J.; Park, J.S.; Ahn, S.; Jang, H.C.; Park, K.H.; Jung, S.I.; Yoon, N.; Kim, D.M.; Hwang, J.H.; Lee, C.S.; Lee, J.H.; Kwak, Y.G.; Kim, E.S.; Park, S.Y.; Park, Y.; Lee, K.S.; Lee, Y.S.; Kim, H.B. Impact of vancomycin MIC on treatment outcomes in invasive Staphylococcus aureus infections. Antimicrob. Agents Chemother., 2017, 61(3), 1-11.
[http://dx.doi.org/10.1128/AAC.01845-16] [PMID: 27956430]
[49]
Czekaj, T.; Ciszewski, M.; Szewczyk, E.M. Staphylococcus haemolyticus - an emerging threat in the twilight of the antibiotics age. Microbiology, 2015, 161(11), 2061-2068.
[http://dx.doi.org/10.1099/mic.0.000178] [PMID: 26363644]
[50]
Viau, R.; Hujer, A.M.; Hujer, K.M.; Bonomo, R.A.; Jump, R.L.P. infectious diseases, a report on diseases caused by bacteria, viruses, fungi and parasites. Br. Rep., 2015, 1, 1-4.
[51]
Alves, G.C. da S. Chequer, F.M.D.; Sanches, C. Concentrações efetivas de vancomicina em crianças: Estudo transversal. Einstein (Sao Paulo), 2019, 17(1), 1-7.
[PMID: 30785491]
[52]
Alves, M.L.P.; Melo, G.A.N.; Yamada, S.S.; Nishiyama, P. Therapeutic monitoring of vancomycin. Acta Sci. Heal Sci., 2012, 34(2), 199-204.
[53]
Ito, H.; Shime, N.; Kosaka, T. Pharmacokinetics of glycopeptide antibiotics in children. J. Infect. Chemother., 2013, 19(2), 352-355.
[http://dx.doi.org/10.1007/s10156-012-0458-8] [PMID: 22872188]
[54]
Rybak, M.J. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin. Infect. Dis., 2006, 42(Suppl. 1), S35.
[http://dx.doi.org/10.1086/491712]

Rights & Permissions Print Cite
Article Metrics
12
© 2024 Bentham Science Publishers | Privacy Policy